| human | Q5 |
| P496 | ORCID iD | 0000-0002-4524-9403 |
| P1153 | Scopus author ID | 55421127700 |
| P108 | employer | University of Toronto | Q180865 |
| University of Alberta | Q640694 | ||
| University of Alberta Hospital | Q7895046 | ||
| Mount Sinai Hospital, Toronto | Q13650874 | ||
| P734 | family name | Huang | Q845104 |
| Huang | Q845104 | ||
| Huang | Q845104 | ||
| P735 | given name | Vivian | Q650494 |
| Vivian | Q650494 | ||
| P106 | occupation | researcher | Q1650915 |
| Q36520699 | A 29-year-old woman with Crohn disease considering pregnancy |
| Q43739841 | A measured approach to Crohn's therapy: check levels and save |
| Q59120251 | Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease |
| Q36233882 | Angioedema associated with Crohn's disease: response to biologics. |
| Q53196223 | Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. |
| Q57810215 | Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology |
| Q88595208 | CD71+ Erythroid Suppressor Cells Promote Fetomaternal Tolerance through Arginase-2 and PDL-1 |
| Q48172992 | Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort |
| Q59120257 | Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study |
| Q30486789 | Distance management of inflammatory bowel disease: systematic review and meta-analysis |
| Q98774524 | Editorial: pregnancy and the gastroenterologist |
| Q88797227 | Experience of menopause in women with inflammatory bowel disease: pilot study |
| Q96349918 | Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease |
| Q37682503 | From conception to delivery: managing the pregnant inflammatory bowel disease patient |
| Q88930148 | Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease |
| Q35670680 | Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. |
| Q50782815 | Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. |
| Q37306723 | Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education |
| Q37120807 | Management of Inflammatory Bowel Disease in Pregnancy: A Practical Approach to New Guidelines |
| Q59337397 | Mode of delivery by an ulcerative colitis mother in a case of twins: Immunological differences in cord blood and placenta |
| Q45937561 | Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. |
| Q88376278 | Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study |
| Q59120277 | Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response |
| Q42117503 | Pancreatitis as a rare manifestation of Behçet disease |
| Q85781813 | Patient awareness of extraintestinal manifestations of inflammatory bowel disease |
| Q34244877 | Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. |
| Q39538749 | Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study |
| Q93002708 | The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn |
| Q38674797 | The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy |
| Q50191205 | Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study. |
Search more.